Wednesday 22 November 2017
Contact US    |    Archive
PR
2 months ago

Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer

NEW YORK and TOKYO, Sept. 14, 2017 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc.

Read on the original site


Hashtags:   

Pfizer

 | 

and

 | 

Astellas

 | 

Announce

 | 

Positive

 | 

Top

 | 

Line

 | 

Results

 | 

from

 | 

Phase

 | 

PROSPER

 | 
Most Popular (6 hours)

Most Popular (24 hours)

Most Popular (a week)

Categories - Countries
All News
All Countries